Full Breakdown
Sen. Josh Hawley Criticizes FDA Over Mifepristone Safety Study
2/12/2026, 7:14:03 AM
Core Event: Hawley's Discontent with FDA's Mifepristone Study
Senator Josh Hawley, a Republican from Missouri, has expressed significant dissatisfaction following a meeting with FDA Commissioner Marty Makary regarding the agency's ongoing safety study of the abortion medication mifepristone. Hawley’s frustration stems from the perception that the FDA's efforts to address his concerns about the drug's safety are inadequate and progressing too slowly.
Background & Context: Mifepristone's Regulatory History
Mifepristone, commonly used for medical abortions, has undergone extensive safety evaluations since its approval. Despite this, Hawley has been vocal about his belief that further scrutiny is necessary. The FDA initially indicated it would not pursue additional studies on mifepristone but later reversed this decision, committing to a new safety study. However, the timeline for completion remains unclear, leading to Hawley's current frustrations.
Official Statements & Responses
In response to Hawley's criticisms, the FDA has stated that it is "planning to complete the study as soon as possible while ensuring we are not cutting any corners from a scientific research standpoint." This statement reflects the agency's commitment to thorough scientific evaluation, despite the delays that have prompted Hawley's discontent.
Criticism & Opposition: Hawley's Perspective
Hawley has been particularly vocal about his lack of confidence in Makary's leadership regarding the mifepristone study. He described the situation as “a dead end” and expressed disappointment that the FDA's actions have not alleviated his concerns. Hawley’s ongoing scrutiny highlights a broader debate over the regulation of abortion medications and the perceived responsiveness of federal agencies to public and political pressures.
Verbatim Quotes
Conflicting Reports & Gaps
While Hawley criticizes the FDA for its slow progress, the agency maintains that it is prioritizing scientific integrity in its study. This discrepancy raises questions about the balance between regulatory thoroughness and the urgency demanded by political figures like Hawley. The lack of a clear timeline for the study's completion remains a point of contention.
What's Next: Future Developments
As the FDA continues its safety study of mifepristone, further developments are expected. Hawley’s ongoing criticism may influence public and political discourse surrounding abortion medication regulation, potentially leading to increased scrutiny of the FDA's processes and timelines.
